Login / Signup

Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study.

Kishore M GaddeMarion L VetterNayyar IqbalElise HardyPeter Öhmannull null
Published in: Diabetes, obesity & metabolism (2017)
This study demonstrated that exenatide QWS-AI reduced HbA1c more than sitagliptin or placebo and was well tolerated.
Keyphrases
  • double blind
  • placebo controlled
  • phase iii
  • clinical trial
  • open label
  • phase ii
  • randomized controlled trial
  • machine learning